In a preclinical model using the NK-92 cell line, combined TIGIT and CD39 or A2AR blockade did increase cytotoxicity against AML cells in vitro, with the authors concluding this approach should be tested clinically (114). This evidence concerns the gene TIGIT and acute myeloid leukemia.